1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Parenteral Drugs (India) Ltd.

Parenteral Drugs (India) Ltd.

PDPL.NS
Parenteral Drugs (India) Ltd.IN flagNational Stock Exchange of India
2.90
INR
- -
- -
101.08MMarket Cap
Parenteral Drugs (India) Ltd.
PDPL.NS
(National Stock Exchange of India)

Recent

price

2.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
116.16
139.87
128.85
219.29
186.54
124.34
119.6
86.46
84.23
82.94
80.1
75.77
10.73
8.06
4.08
2.85
2.85
Revenue per Share
3.19
12.57
5.59
16.11
1.71
-20.64
-41.69
-15.15
-22.69
-39.09
-39.52
-37.5
-49.61
-38.26
-40.82
-25.61
-25.61
Basic EPS, GAAP
-9.54
-43.51
-26.67
-27.57
-12.16
-49.67
-72.94
-58.36
-2.44
-17.45
44.93
55.53
159.99
37.69
-0.04
-0.16
- -
Free Cash Flow per Basic Share
0.56
1.13
1.2
2
0.89
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
32.94
86.06
134.24
174.21
21.88
11.61
-30.08
-38.82
-58.88
-143.03
-182.62
-222.52
-257.94
-296.3
-337.07
10
10
Book Value per Share
32.94
86.14
71.08
104.56
84.66
79.47
37.62
18.58
-5.48
33.83
-11.75
-45.66
-149.85
-188.21
-228.98
-276.32
-276.29
Tangible Book Value per Share
15
15
21
19
26
26
26
30
30
30
30
30
30
30
30
30
30
Basic Weighted Avg Shares
1,735
2,130
2,694
4,145
4,822
3,216
3,094
2,578
2,511
2,473
2,388
2,259
320
240
122
85
85
Sales/Revenue/Turnover
8.13
16.09
12.72
13.8
7.84
-0.01
-11.9
-18.65
-6.77
-22.85
-9.82
-10.02
-271.2
-131.48
-239.15
-649.25
-649.25
Operating Margin (%)
28
45
70
90
126
145
230
186
310
228
249
242
691
173
173
401
401
Depreciation Expense
48
191
117
304
44
-534
-1,078
-452
-677
-1,165
-1,178
-1,118
-1,479
-1,141
-1,217
-764
-764
Net Income, GAAP
36.52
18.5
37.97
23.37
45.87
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
2.75
8.99
4.34
7.35
0.92
-16.6
-34.86
-17.52
-26.94
-47.13
-49.34
-49.49
-462.23
-474.81
-1,000.31
-898.77
-898.77
Profit Margin (%)
698
1,306
1,698
1,939
1,852
-528
304
340
51
-1,541
-3,058
-4,935
-8,102
-9,382
-10,756
-11,337
-11,337
Working Capital
991
1,043
1,881
2,558
3,258
2,096
3,663
4,000
4,123
4,358
3,807
3,086
330
305
305
1,072
1,072
LT Debt
492
1,312
2,808
3,298
3,510
3,497
2,469
2,030
1,278
1,009
-172
-1,362
-4,468
-5,612
-6,828
-8,239
-8,239
Total Equity
6.87
14.16
5.9
8.12
3.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
3.75
9.98
3.32
5.77
0.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
10.6
21.24
5.67
9.98
2.29
-123.3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-407.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'22
ST Debt
- -
- -
- -
LT Borrowings
1,073
- -
1,072
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
- -
30
Market Capitalization
85
113
107

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'22
Total Current Assets
673
- -
671
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
6
- -
10
Total Current Liabilities
12,183
- -
12,008
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
76.72%
197.9%
20.67%
Free Cash Flow
57.15%
74.16%
335.65%
Net Income, GAAP
14.08%
-5.25%
-37.26%
Sales/Revenue/Turnover
-22.37%
-39.14%
-30.17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
87
73
72
7
240
2021
29
46
20
26
122
2022
29
24
14
18
85

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-9.29
-9.5
-8.77
- -
-38.26
2021
-10.81
-11.29
-10.39
- -
-40.82
2022
-10.74
-11.27
-11.58
- -
-25.61

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
DMK Pharmaceuticals Corporation (0A4X.L)
Quantum BioPharma Ltd. (QNTM)
Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SS)
Lumiera Health Inc. (NHP.V)
Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
Business
Parenteral Drugs (India) Limited Parenteral Drugs (India) Limited manufactures intravenous fluids and pharmaceutical formulations, serving as India's largest producer of IV fluids with an annual capacity exceeding 300 million bottles. The company offers a broad portfolio of products including large-volume IV infusions such as Dextrose IP in 5%, 10%, 20%, and 25% concentrations, Ringer Lactate IP, Mannitol 10% and 20%, peritoneal dialysis solutions, and irrigation solutions like 1.5% Glycine; oncology injections such as 5FU-PAR, BAZIPAR (Dacarbazine), Cytarapar (Cytarabine), Docepar (Docetaxel), Etopar (Etoposide), and Womaplat (Carboplatin); anesthesia products including Sevoplan (Sevoflurane) and Isoplan (Isoflurane); anti-infectives like Ciprofloxacin and Metronidazole injections; and additional offerings such as Paracetamol 1000mg (Tamolgan), sterile water for injection, veterinary infusions, inhalation products, antibiotics, analgesics, antifungals, ophthalmics, topicals, oral liquids, dry powders, tablets, and capsules. It operates three manufacturing facilities across India, with headquarters in Indore, Madhya Pradesh, and additional presence in locations like Pune and Mumbai; founded in 1983 as a private limited company and converted to public limited status in 1994, the company primarily targets domestic healthcare providers and exports to international markets while providing contract manufacturing services. In recent developments, a Mumbai bankruptcy court approved the acquisition of Parenteral Drugs (India) Limited by IHL Lifesciences in early 2025, marking a significant ownership transition under insolvency proceedings with full creditor approval.